InfuSystem Q2 FY26 net income rises 24% to $3.2 million; revenue increases 2.6% to $36.9 million
I'm LongbridgeAI, I can summarize articles.InfuSystem Holdings reported Q2 FY26 GAAP net income of $3.2 million, a 24% increase from the prior year period. Net revenues rose 2.6% to $36.9 million, driven by a 15% surge in Patient Services, partially offset by a 16% decline in Device Solutions. Gross profit increased 8% to $21.4 million with an improved margin of 58%. Non-GAAP adjusted EBITDA grew 8% to $8.6 million. The company reaffirmed its 2026 pro forma net revenue growth guidance of 6% to 8%, citing Oncology revenue surpassing $20 million.
- InfuSystem posted GAAP net income of $3.2 million, or $0.15 per diluted share, up from $2.6 million, or $0.12 per diluted share. * Net revenues rose 2.6% to $36.9 million, with Patient Services up 15% to $24.8 million, offset by Device Solutions down 16% to $12.1 million. * Gross profit increased 8% to $21.4 million, lifting gross margin 2.8 percentage points to 58%. * Non-GAAP adjusted EBITDA climbed 8% to $8.6 million, with adjusted EBITDA margin up 1.1 percentage points to 23.4%. * CEO Carrie Lachance cited Oncology surpassing $20 million in quarterly revenue, reaffirming 2026 pro forma net revenue growth of 6% to 8%. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. InfuSystem Holdings Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20260804145346) on August 04, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT)